BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2026.
World J Clin Oncol. Jan 24, 2026; 17(1): 114012
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.114012
Table 1 Baseline characteristics between survivors and non-survivors, n (%)
Variable
Total (n = 1142)
Survivors (n = 615)
Non-survivors (n = 527)
Statistic
P value
Gender
    Male783 (68.56)407 (66.18)376 (71.35)
    Female359 (31.44)208 (33.82)151 (28.65)
Age (years)
    ≤ 2947 (4.12)36 (76.60)11 (23.40)
    30-39202 (17.69)132 (65.35)70 (34.65)
    40-49522 (45.70)268 (51.34)254 (48.66)
    50-59279 (24.43)138 (49.46)141 (50.54)
    60-6988 (7.71)41 (46.59)47 (53.41)
    ≥ 704 (0.35)0 (0)4 (100)
Tumor stage (%)χ² = 6.080.193
    I0.470.730.23
    II5.447.073.90
    III54.6156.6552.44
    IVa35.4634.8636.10
    IVb4.023.664.36
TAM (U/mL)89.27 ± 12.4387.73 ± 11.0990.89 ± 13.60t = 1.420.159
TSGF (U/mL)54.40 ± 17.2254.37 ± 17.1954.43 ± 17.28t = 0.050.959
NSE (ng/mL)2.61 ± 1.952.55 ± 2.112.68 ± 1.79t = 0.610.539
CEA (mg/L)1.41 ± 1.481.22 ± 0.951.58 ± 1.83t = 2.360.019
Feritin (ng/mL)133.42 ± 76.1197.32 ± 68.38167.22 ± 67.04t = 9.84< 0.001
AFP (ng/mL)1.73 ± 2.091.65 ± 2.121.82 ± 2.05t = 0.770.444
AST (U/L)23.45 ± 16.3023.58 ± 17.1423.30 ± 15.35t = -0.260.798
ALT (U/L)26.83 ± 29.5927.39 ± 29.3026.22 ± 29.93t = -0.600.547
ALP (U/L)75.67 ± 27.4375.33 ± 28.2676.04 ± 26.52t = 0.380.706
LDH (U/L)172.59 ± 42.86169.30 ± 42.23176.27 ± 43.32t = 2.360.018
GGT (U/L)33.87 ± 53.8731.13 ± 27.6336.90 ± 72.44t = 1.550.122
5-NT (U/L)6.07 ± 5.515.91 ± 5.146.25 ± 5.89t = 0.890.371
GPDA (U/L)67.91 ± 21.3868.18 ± 20.0667.61 ± 22.76t = -0.380.704
ADA (U/L)15.18 ± 23.8014.58 ± 17.9715.83 ± 28.91t = 0.750.450
MAO (U/L)4.77 ± 2.374.75 ± 2.334.80 ± 2.41t = 0.260.794


Write to the Help Desk